ReVISION 2
Argus Cognitive, Inc. · Decision date Sep 9, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for ReVISION 2, submitted by Argus Cognitive, Inc. of Hanover, NH, under 510(k) K251417 with a decision date of September 9, 2026. The device is regulated under 21 CFR 892.2050 as a Class II Medical Image Management and Processing System, product code QIH, in the Radiology panel. SESE is a 510(k) clearance, not a premarket approval. The submission lists K201632 (TomTec-Arena TTA2) as primary predicate and K223322 (ReVISION 1.0) as secondary predicate.
ReVISION 2 is described as standalone, web-based software as a medical device that accepts DICOM data from compatible ultrasound systems and produces a 3D right ventricular surface model through an AI contouring module, with volumetric, strain and curvature outputs and a structured outcome report. Its stated indications cover quantification and reporting of right ventricular structure and function in adults over 21 with suspected disease; pediatric use is excluded. The summary states no clinical testing was performed and that equivalence rests on nonclinical and analytical validation. The source does not disclose performance results, and the public record shows no authorized predetermined change control plan.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 9, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K251417
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Argus Cognitive, Inc.
- Product code
- QIH
- Decision code
- SESE
- Decision date
- Sep 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated Radiological Image Processing Software.
- Applicant
- Argus Cognitive, Inc.
- Product code
- QIH
- FDA device class
- 2
FDA decision timeline
K251417 received
Application receipt date recorded by FDA.
K251417 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Clever OneK260372 | Ewoosoft Co., Ltd. | 510(k) clearance | Nov 4, 2026 | FDA |
PeekMed webK262667 | Peek Health, S.A. | 510(k) clearance | Nov 4, 2026 | FDA |
CINA-Aneurysm+K262147 | AVICENNA.AI | 510(k) clearance | Oct 19, 2026 | FDA |
Ligence HeartK261733 | UAB Ligence | 510(k) clearance | Oct 7, 2026 | FDA |
NeuroDRK262134 | Deep Reasoning Ai, Inc. | 510(k) clearance | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Argus Cognitive, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Hanover, NH
Sources and methodology
- Original FDA record: K251417
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


